As at September 30, 2015, the Company had working capital of $1,019,456. These funds are expected to fund the operations of the Company into the second quarter of 2016.
Outlook
The Company’s priorities for the next year are to focus on identifying and developing precision medicine solutions for AD and ALS.
Regarding AD, the Company will continue to expand its Intellectual Property (IP) estate by identifying novel epitope targets on misfolded strains of proteins beta Amyloid and Tau. The Company’s proprietary technique, ProMISTM, and potentially other complementary and proprietary computational methods under development, will be employed to identify and confirm such novel targets. Subsequent to identification of these targets and submission of initial IP claims, the Company will be in a position to enter the product development phase by elaborating and developing specific therapeutics and companion diagnostics aimed at these targets for Alzheimer’s disease.
Regarding ALS, and given the Company’s robust IP estate, in particular its ownership of the exclusive rights to thegenus patent relating to misfolded SOD1 in ALS, ProMIS Neurosciences is actively looking to achieve a collaborative development partnership in this field.
On Thursday, November 12, Bigger Capital will be hosting an investor dinner for an exclusive group of investors. At the dinner, investors will have the opportunity to network and to meet management of ProMis Neurosciences. ProMis is a development stage biotech company harnessing the power of precision medicine to conquer Alzheimer’s disease and ALS.
We believe ProMis could be an acquisition target for many big pharma companies in the likely event that it’s precision technology uncovers targets critical to treating Alzheimers’ and / or ALS. At the current Enterprise Value of $8mm, we believe the risk / reward profile of acquiring this powerful technology is quite compelling.
If you are interested in learning more about this opportunity, please read our detailed investment thesis and join us on Thursday. Space is limited. For logistics, please contact Michael Bigger, using the contact button located at the top of the blog page.
of Interest: Promis Neurosciences Investment Thesis
Michael Bigger. Follow me on Twitter and StockTwits.
Disclaimer: Bigger Capital and related entities are long 14.3MM shares of PMN. ProMIS is in a re-launch mode and it is not suitable for the majority of investors. The likely outcome of an investment is a loss of principal. Take our opinions with a grain of salt. If you find yourself relying on our views to make an investment decision it means you definitely did not do your homework about this situation. Please do not rely on our views, instead use the information as a jumping off point to begin your own independent due diligence.